STAT News
JULY 14, 2022
Sek Kathiresan, cardiologist and CEO of Verve Therapeutics, joins us to explain the company’s work on preventing heart disease with genome editing. We also break down the latest news in the life sciences, including a long-awaited victory for Novavax and ostensible good news for biotech.
XTalks
APRIL 15, 2021
New advances in heart failure genomics are helping to address this challenge. Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. Watch this on-demand webinar to hear from these experts.
XTalks
NOVEMBER 19, 2021
This is a part of the precision cardiology approach and could lead to their use as prognostic indicators. Dr. Januzzi describes a “biomarker Phase II,” which involves applying an unbiased inductive approach using omics-based approaches, such as proteomics, metabolomics, genomics and transcriptomics, to identify plausible drug-marker pairs.
Expert insights. Personalized for you.
98 
Let's personalize your content